Eli Lilly and Co (LLY) : London Co Of Virginia scooped up 207,398 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,570,523 shares of Eli Lilly and Co which is valued at $286,427,355.Eli Lilly and Co makes up approximately 2.23% of London Co Of Virginia’s portfolio.
Other Hedge Funds, Including , Polar Capital Llp reduced its stake in LLY by selling 718,778 shares or 90.55% in the most recent quarter. The Hedge Fund company now holds 75,000 shares of LLY which is valued at $6,016,500. Eli Lilly and Co makes up approx 0.11% of Polar Capital Llp’s portfolio. Quadrature Capital Ltd added LLY to its portfolio by purchasing 161,779 company shares during the most recent quarter which is valued at $12,977,911. Eli Lilly and Co makes up approx 0.91% of Quadrature Capital Ltd’s portfolio.1st Source Bank reduced its stake in LLY by selling 316 shares or 0.93% in the most recent quarter. The Hedge Fund company now holds 33,613 shares of LLY which is valued at $2,786,182. Eli Lilly and Co makes up approx 0.30% of 1st Source Bank’s portfolio.
Eli Lilly and Co closed down -0.52 points or -0.67% at $77.23 with 35,44,701 shares getting traded on Thursday. Post opening the session at $77.75, the shares hit an intraday low of $76.8 and an intraday high of $78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.